Open Access Open Access  Restricted Access Subscription or Fee Access

Diverse microRNAs Expressed in Five Prominent Cancers Worldwide

Ariya SS, Baby Joseph


MicroRNA being a small RNA molecule plays an important role in the process of transcription of gene to mRNA. The importance of several numbers of microRNAs has been studied till date. They are capable of aiding in normal functioning of an organism. At the same time, their expression can have serious effects in different diseases. Many numbers of miRNAs has been reported to play vital roles in progression as well as control of cancers. In some cases, the downregulation or upregulation of certain miRNA are reported to be the cause for diseases. But in some cases, certain miRNAs are reported to be capable of controlling the diseases either by exhibiting a high range of expression or expressing in low rate. This article concentrates on some of the miRNAs involved in breast, lung, colon, ovarian and hepatocellular carcinomas.


Keywords: miRNA, non-coding RNA, carcinoma, breast cancer, colon cancer, hepatocellular carcinoma, lung cancer, ovarian cancer, PCR, microarray


Cite this Article

Ariya S.S., Baby Joseph. Diverse microRNAs Expressed in Five Prominent Cancers Worldwide. Research & Reviews: A Journal of Bioinformatics. 2018; 5(1):


miRNA, non coding RNA, carcioma, breast cancer, colon cancer, hepatocellular carcinoma, lung cancer, ovarian cancer, PCR and microarray

Full Text:



Kaladhar B Reddy. MicroRNA (miRNA) in cancer. Cancer Cell International 2015; 15:38. DOI: 10.1186/s12935-015-0185-1

Yong Peng and Carlo M Croce. The role of MicroRNAs in human cancer. Signal Transduction and Targeted Therapy; 2016 1, 15004; doi:10.1038/sigtrans.2015.4

Borchert GM, Lanier W, Davidson BL. RNA polymerase III transcribes human microRNAs. Nat Struct Mol Biol 2006; 13: 1097–1101.

Macfarlane LA, Murphy PR. MicroRNA: biogenesis, function and role in cancer. Curr Genomics 2010; 11: 537–561.

Zhou WB, Zhong CN, Luo XP, Zhang YY, Zhang GY, Zhou DX, Liu LP. miR-625 suppresses cell proliferation and migration by targeting HMGA1 in breast cancer. Biochem Biophys Res Commun. Feb 19 2016; 470(4):838-44. doi:10.1016/j.bbrc.2016.01.122.

Kim SJ, Shin JY, Lee KD, Bae YK, Sung KW, Nam SJ, Chun KH. MicroRNA let-7a suppresses breast cancer cell migration and invasion through downregulation of C-C chemokine receptor type 7. Breast Cancer Res. 2012 Jan 18;14(1):R14.

S A Joosse, VMuller, B Steinbach, K Pantel and H Schwarzenbach. Circulating cell-free cancer-testis MAGE-A RNA, BORIS RNA, let-7b and miR-202 in the blood of patients with breast cancer and benign breast diseases. British Journal of Cancer 2014; 111, 909–917 | doi: 10.1038/bjc.2014.360

Nana Li, Yuan Miao, Yujia Shan, Bing Liu, Yang Li, Lifen Zhao and Li Jia. MiR-106b and miR-93 regulate cell progression by suppression of PTEN via PI3K/Akt pathway in breast cancer. Cell Death and Disease 2017; 8, e2796; doi:10.1038/cddis.2017.119

Motawi, Tarek & Abdel Hamid Sadik, Nermin & Shaker, Olfat & Rafik El Masry, Maha & Mohareb, Fady. Study of microRNAs-21/221 as potential breast cancer biomarkers in Egyptian women. Gene. 2016; 590. 10.1016/j.gene.2016.01.042.

Yan Y, Zhang F, Fan Q, Li X, Zhou K. Breast cancer-specific TRAIL expression mediated by miRNA response elements of let-7 and miR-122. Neoplasma. 2014; 61(6):672-9. doi: 10.4149/neo_2014_082.

Wen-binZhou, Cai-nengZhong, Xun-pengLuo, Ya-yuanZhang, Gui-yingZhang, Dong-xianZhou, Li-pingLiu. miR-625 suppresses cell proliferation and migration by targeting HMGA1 in breast cancer. Biochemical and Biophysical Research Communications February 2016; Volume 470, Issue 4, 19 Pages 838-844

Ulrich Lehmann, Thomas Streichert, Benjamin Otto, Cord Albat, Britta Hasemeier, Henriette Christgen, Elisa Schipper, Ursula Hille, Hans H Kreipe and Florian Länger. Identification of differentially expressed microRNAs in human male breast cancer. BMC Cancer 2010; 10:109 DOI: 10.1186/1471-2407-10-109

Eleni van Schooneveld, Maartje CA Wouters, Ilse Van der Auwera, Dieter J Peeters, Hans Wildiers, Peter A Van Dam, Ignace Vergote, Peter B Vermeulen, Luc Y Dirix and Steven J Van Laere. Expression profiling of cancerous and normal breast tissues identifies microRNAs that are differentially expressed in serum from patients with (metastatic) breast cancer and healthy volunteers. Breast Cancer Research 2012; 14:R34. DOI: 10.1186/bcr3127

Liu N, Xia WY, Liu SS, Chen H, Sun L, Liu MY, Li LF, Lu HM, Fu YJ, Wang P, Wu H, Gao JX. MicroRNA-101 targets von Hippel-Lindau tumor suppressor (VHL) to induce HIF1α mediated apoptosis and cell cycle arrest in normoxia condition. Sci Rep. 2016 Feb 4; 6 :20489. doi: 10.1038/srep20489.

Yusuke Yamamoto, Nobuyoshi Kosaka, Minoru Tanaka, Fumiaki Koizumi, Yae Kanai, Takayuki Mizutani, Yoshiki Murakami, Masahiko Kuroda, Atsushi Miyajima, Takashi Kato and Takahiro Ochiya. MicroRNA-500 as a potential diagnostic marker for hepatocellular carcinoma. Biomarkers 2009; 14: 529–38.

Zhu Z, Wang S, Zhu J, Yang Q, Dong H, Huang J. MicroRNA-544 down-regulates both Bcl6 and Stat3 to inhibit tumor growth of human triple negative breast cancer. Biol Chem. 2016 Oct 1; 397(10):1087-95. doi: 10.1515/hsz-2016-0104.

Pooja Joshi, Justin Middleton, Young-Jun Jeon, Michela Garofalo. MicroRNAs in lung cancer. World J Methodol 2014 June 26; 4(2): 59-72

Johnson SM, Grosshans H, Shingara J, et al. RAS is regulated by the let-7 microRNA family. Cell 2005;120:635–647

S. Patrick Nana-Sinkam, MD and Mark W. Geraci, MD. MicroRNA in Lung Cancer. Journal of Thoracic Oncology. 2006;1: 929–931

Eder, Matthias, MD; Scherr, Michaela,. MicroRNA and lung cancer. The New England Journal of Medicine; Boston Jun 9, 2005; 352.23: 2446-8.

Nozomu Yanaihara, Natasha Caplen, Elise Bowman, Masahiro Seike, Kensuke Kumamoto, Ming Yi, Robert M. Stephens, Aikou Okamoto, Jun Yokota, Tadao Tanaka, George Adrian Calin, Chang-Gong Liu, Carlo M. Croce and Curtis C. Harris. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell MARCH 2006; 9, 189–198. doi: 10.1016/j.ccr.2006.01.025

Ebi H, Sato T, Sugito N, Hosono Y, Yatabe Y, Matsuyama Y, Yamaguchi T, Osada H, Suzuki M, Takahashi T. Counterbalance between RB inactivation and miR-17-92 overexpression in reactive oxygen species and DNA damage induction in lung cancers. Oncogene 2009 Sep 24; 28(38):3371-9. doi: 10.1038/onc.2009.201.

P-Y Lin, S-L Yu and P-C Yang. MicroRNA in lung cancer. British Journal Of Cancer 2010 Oct 12; 103(8): 1144–1148. doi: 10.1038/sj.bjc.6605901

He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S, Powers S, Cordon-Cardo C, Lowe SW, Hannon GJ, Hammond SM. A microRNA polycistron as a potential human oncogene. Nature 2005; 435:828–833.

Dews M, Homayouni A, Yu D, Murphy D, Sevignani C, Wentzel E, Furth EE, Lee WM, Enders GH, Mendell JT, Thomas-Tikhonenko A. Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet. 2006; 38:1060–1065.

Johnson CD, Esquela-Kerscher A, Stefani G, Byrom M, Kelnar K, Ovcharenko D, Wilson M, Wang X, Shelton J, Shingara J, Chin L, Brown D, Slack FJ. The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res. 2007; 67:7713–7722.

Liu B, Peng XC, Zheng XL, Wang J, Qin YW. MiR-126 restoration down-regulate VEGF and inhibit the growth of lung cancer cell lines in vitro and in vivo. Lung Cancer. 2009 Nov; 66(2):169-75.

Bommer GT, Gerin I, Feng Y, Kaczorowski AJ, Kuick R, Love RE, Zhai Y, Giordano TJ, Qin ZS, Moore BB, MacDougald OA, Cho KR, Fearon ER. p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol. 2007 Aug 7; 17(15):1298-307.

He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y, Xue W, Zender L, Magnus J, Ridzon D, Jackson AL, Linsley PS, Chen C, Lowe SW, Cleary MA, Hannon GJ. A microRNA component of the p53 tumour suppressor network. Nature. 2007 Jun 28; 447(7148):1130-4.

Y Murakami, T Yasuda, K Saigo, T Urashima, H Toyoda, T Okanoue and K Shimotohno. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene 2006; 25, 2537–2545.

Asahiro Morishita and Tsutomu Masaki. miRNA in hepatocellular carcinoma. Hepatology Research Wiley Publishing Asia Pty Ltd 6 August 2014; DOI: 10.1111/hepr.12386

Laura Gramantieri, Manuela Ferracin, Francesca Fornari, Angelo Veronese, Silvia Sabbioni, Chang-Gong Liu, George A. Calin, Catia Giovannini, Eros Ferrazzi, Gian Luca Grazi, Carlo M. Croce, Luigi Bolondi and Massimo Negrini. Cyclin G1 Is a Target of miR-122a, a MicroRNA Frequently Down-regulated in Human Hepatocellular Carcinoma. Cancer research Molecular Biology, Pathobiology, and Genetics 2007; DOI: 10.1158/0008-5472.CAN-06-4607.

Anuradha Budhu, Hu-Liang Jia, Marshonna Forgues, Chang-Gong Liu, David Goldstein, Amy Lam, Krista A. Zanetti, Qing-Hai Ye, Lun-Xiu Qin, Carlo M. Croce, Zhao-You Tang, and Xin Wei Wang.Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology March 2008; DOI: 10.1002/hep.22160

HangSu, Jian-RongYang, TengXu, JunHuang, LiXu, YunfeiYuan andShi-MeiZhuang. MicroRNA-101 Down-regulated in Hepatocellular Carcinoma, Promotes Apoptosis and Suppresses Tumorigenicity. Cancer Research 2009; 69:1135-1142. DOI: 10.1158/0008-5472.CAN-08-2886

Jian Xu, Chen Wu, Xu Che, Li Wang, Dianke Yu, Tongwen Zhang, Liming Huang, Hui Li, Wen Tan, Chengfeng Wang and Dongxin Lin. Circulating MicroRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Cancer Res Molecular Carcinogenesis February 1 2009; 69: (3). 50:136–142 (2011)

Yoshio Miki, Jeff Swensen, Donna Shattuck-Eidens, P. Andrew Futreal, Keith Harshman, Sean Tavtigian, Qingyun Liu, Charles Cochran, L. Michelle Bennett,Wei Ding, Russell Bell, Judith Rosenthal, Charles Hussey, Thanh Tran, Melody McClure,Cheryl Frye, Tom Hattier, Robert Phelps, Astrid Haugen-Strano, Harold Katcher, Kazuko Yakumo, Zahra Gholami, Daniel Shaffer,Steven Stone, Steven Bayer, Christian Wray, Robert Bogden, Priya Dayananth,John Ward, Patricia Tonin, Steven Narod, Pam K. Bristow, Frank H. Norris, Leah Helvering, Paul Morrison, Paul Rosteck, Mei Lai, J. Carl Barrett, Cathryn Lewis, Susan Neuhausen, Lisa Cannon-Albright, David Goldgar, Roger Wiseman, Alexander Kamb,Mark H. Skolnick. Strong Candidate for the Breast and Ovarian Cancer Susceptibility Gene BRCA1, Science October 1994; VOL.266, 7.

Nuo Yang, Sippy Kaur, Stefano Volinia, Joel Greshock, Heini Lassus, Kosei Hasegawa, Shun Liang, Arto Leminen, Shan Deng, Lori Smith, Cameron N. Johnstone, Xian-Ming Chen, Chang-Gong Liu, Qihong Huang, Dionyssios Katsaros, George Adrian Calin, Barbara L. Weber, Ralf Bützow, Carlo M. Croce, George Coukos and Lin Zhang. MicroRNA Microarray Identifies Let-7i as a Novel Biomarker and Therapeutic Target in Human Epithelial Ovarian Cancer. Cancer Research 2008; 68(24):10307–14, DOI: 10.1158/0008-5472.CAN-08-1954.

Neetu Dahiya, Cheryl A. Sherman-Baust, Tian-Li Wang, Ben Davidson, Ie-Ming Shih, Yongqing Zhang, William Wood III, Kevin G. Becker, Patrice J. MicroRNA Expression and Identification of Putative miRNA Targets in Ovarian Cancer. PLoS ONE June 2008; Volume 3 : Issue 6 | e2436.

Marilena V. Iorio, Rosa Visone, Gianpiero Di Leva, Valentina Donati, Fabio Petrocca, Patrizia Casalini, Cristian Taccioli, Stefano Volinia, Chang-Gong Liu, Hansjuerg Alder, George A. Calin, Sylvie Ménard and Carlo M. Croce. MicroRNA Signatures in Human Ovarian Cancer. Cancer Research, Cell, Tumor, and Stem Cell Biology 2007; 67(18):8699–707. DOI: 10.1158/0008-5472.CAN-07-1936.

Hua Yang, William Kong, Lili He, Jian-Jun Zhao, Joshua D. O'Donnell, Jiawang Wang, Robert M. Wenham, Domenico Coppola, Patricia A. Kruk, Santo V. Nicosia and Jin Q. Cheng. MicroRNA Expression Profiling in Human Ovarian Cancer: miR-214 Induces Cell Survival and Cisplatin Resistance by Targeting PTEN. Cancer Research 2008; 68(2):425–33. DOI: 10.1158/0008-5472.CAN-07-2488.

Kimberly E. Resnick, Hansjuerg Alder, John P. Hagan, Debra L. Richardson,Carlo M. Croce and David E. Cohn. The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecologic Oncology 2009; 112, 55–59.

Antonio Sorrentino, , Chang-Gong Liu, Antonio Addario, Cesare Peschle, Giovanni Scambia and Cristiano Ferlini. Role of microRNAs in drug-resistant ovarian cancer cells. Gynecologic Oncology 2008; 111, 478–486.

Xiaoxia Hu, Dusten M. Macdonald, Phyllis C. Huettner, Zhihui Feng, Issam M. El Naqa, Julie K. Schwarz, David G. Mutch, Perry W. Grigsby, Simon N. Powell and Xiaowei Wang. A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer. Gynecologic Oncology 2009; 114, 457–464.

Eun Ji Nam, Heejei Yoon, Sang Wun Kim, Hoguen Kim, Young Tae Kim, Jae Hoon Kim, Jae Wook Kim and Sunghoon Kim. MicroRNA Expression Profiles in Serous Ovarian Carcinoma. Clinical Cancer Research May 2008; DOI: 10.1158/1078-0432.CCR-07-1731.

Li-Min Guo, Yong Pu, Zhe Han, Tao Liu, Yi-Xuan Li, Min Liu, Xin Li and Hua Tang. MicroRNA-9 inhibits ovarian cancer cell growth through regulation of NF-κB1. FEBS Journal 276 2009; 5537–5546.

Boye Schnack Nielsen, Stine Jørgensen, Jacob Ulrik Fog, Rolf Søkilde, Ib Jarle Christensen, Ulla Hansen, Nils Brunner, Adam Baker, Søren Møller and Hans Jørgen Nielsen. High levels of microRNA-21 in the stroma of colorectal cancers predict short disease-free survival in stage II colon cancer patients. Clin Exp Metastasis 2011; 28:27–38. DOI 10.1007/s10585-010-9355-7.

E Bandrés, E Cubedo, X Agirre, R Malumbres, R Zárate, N Ramirez, A Abajo, A Navarro, I Moreno, M Monzó and J García-Foncillas. Identification by Real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues. Bio Med Central, Molecular Cancer 2006; 5:29.

Troels Schepeler, Jørgen T. Reinert, Marie S. Ostenfeld, Lise L. Christensen, Asli N. Silahtaroglu, Lars Dyrskjøt, Carsten Wiuf, Frank J. Sørensen, Mogens Kruhøffer, Søren Laurberg, Sakari Kauppinen, Torben F. Ørntoft and Claus L. Andersen. Diagnostic and Prognostic MicroRNAs in Stage II Colon Cancer. Cancer Research 2008; 68(15):6416–24.

Go Nakajima, Kazuhiko Hayashi, Yaguang Xi, Kenji Kudo, Kazumi Uchida, Ken Takasaki, Masakazu Yamamoto and Jingfang Ju. Non-coding MicroRNAs hsa-let-7g and hsa-miR-181b are Associated with Chemoresponse to S-1 in Colon Cancer. Cancer Genomics and Proteomics September-October 2006; vol. 3 no. 5 317-324.

Alexander Link, Francesc Balaguer, Yan Shen, Takeshi Nagasaka, Juan José Lozano, C. Richard Boland and Ajay Goel. Fecal MicroRNAs as Novel Biomarkers for Colon Cancer Screening. Cancer Epidemiol Biomarkers Prev July 2010; 19(7). DOI: 10.1158/1055-9965.EPI-10-0027.

Aaron L, Amy J French, Pedro M Borralho, Venugopal Thayanithy, Ann L Oberg, Kevin AT Silverstein, Bruce W Morlan, Shaun M Riska, Lisa A Boardman, Julie M Cunningham, Subbaya Subramanian, Liang Wang, Tom C Smyrk, Cecilia MP Rodrigues, Stephen N Thibodeau and Clifford J Steer. Human colon cancer profiles show differential microRNA expression depending on mismatch repair status and are characteristic of undifferentiated proliferative states. BioMed Central Cancer 2009; 9:401.

Peng Wang, Fangdong Zou, Xiaodong Zhang, Hua Li, Austin Dulak, Robert J. Tomko Jr., John S. Lazo, Zhenghe Wang, Lin Zhang and Jian Yu. MicroRNA-21 Negatively Regulates Cdc25A and Cell Cycle Progression in Colon Cancer Cells. Cancer research 2009; 69(20):8157–65.

Hiroko Ogata-Kawata, Masashi Izumiya, Daisuke Kurioka, Yoshitaka Honma, Yasuhide Yamada, Koh Furuta, Toshiaki Gunji, Hideki Ohta, Hiroyuki Okamoto, Hikaru Sonoda, Masatoshi Watanabe, Hitoshi Nakagama, Jun Yokota, Takashi Kohno, Naoto Tsuchiya. Circulating Exosomal microRNAs as Biomarkers of Colon Cancer. PLOS ONE April 2014; Volume 9 : Issue 4 e92921.

Joseph J. Sung, Wai Sing Chong, Hongchuan Jin, Emily KY Lam, Vivian Y. Shin, Jun Yu, Terence CW Poon, Simon S. Ng, Enders KO Ng. Differential expression of microRNAs in plasma of colorectal cancer patients: A potential marker for colorectal cancer screening. British Soceity of Gastroenterology February 06, 2009.



  • There are currently no refbacks.

Copyright (c) 2018 Research & Reviews: A Journal of Bioinformatics